Evidence map›Paper›PMID 35244756›Full record

Trial reportAnnals of hematology2022

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.

Kayoko Murayama, Toru Kiguchi, Koji Izutsu, Yoshihiro Kameoka, Michihiro Hidaka, Harumi Kato, Shinya Rai, Junya Kuroda, Kenichi Ishizawa, Satoshi Ichikawa and 4 more

Abstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kayoko MurayamaDepartment of Hematology, Gunma Prefectural Cancer Center, Ota, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan. kiguchi-t@umin.ac.jp.
Koji IzutsuDepartment of Hematology Tokyo, National Cancer Center Hospital, Tokyo, Japan.
Yoshihiro KameokaDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine and Faculty of Medicine, Akita, Japan.
Michihiro HidakaDepartment of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Harumi KatoDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Shinya RaiDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kenichi IshizawaDepartment of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan.
Satoshi IchikawaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kiyoshi AndoDepartment of Hematology & Oncology, Tokai University School of Medicine, Isehara, Japan.
Michinori OguraDepartment of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan.
Koji FukushimaMedical Affairs Department, SymBio Pharmaceutical Ltd., Research & Development Division, Tokyo, Japan.
Yasuhito TeruiDepartment of Hematology Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell lymphoma (rrDLBCL). The primary endpoint was overall response rate (ORR). Autologous stem cell transplantation-ineligible rrDLBCL patients with ≤ 2 prior chemotherapy regimens received R 375 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideHumansJapanMiddle AgedRituximabTransplantation, AutologousBendamustine HydrochlorideRituximabBendamustine hydrochlorideDiffuseLarge B cellLymphomaRecurrenceRituximabSalvage therapy

Identifiers

PMID35244756
PMCPMC8993776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.